Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) in a research note issued on Tuesday, Marketbeat reports. The brokerage set an "overweight" rating and a $25.00 price target on the stock. Cantor Fitzgerald's price target points to a potential upside of 338.60% from the stock's previous close.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and set a $24.00 target price on shares of Trevi Therapeutics in a report on Tuesday, May 20th. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Wall Street Zen downgraded shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Finally, Raymond James Financial upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $20.88.

Trevi Therapeutics Stock Performance

TRVI traded up $0.23 during trading on Tuesday, reaching $5.70. The stock had a trading volume of 2,399,414 shares, compared to its average volume of 1,401,113. The business has a 50-day moving average of $6.32 and a 200-day moving average of $5.36. Trevi Therapeutics has a one year low of $2.36 and a one year high of $7.48. The stock has a market cap of $668.55 million, a PE ratio of -12.67 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. Equities research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its holdings in Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock valued at $578,000 after buying an additional 2,935 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Trevi Therapeutics by 14.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock valued at $713,000 after acquiring an additional 22,145 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Trevi Therapeutics in the fourth quarter valued at about $49,000. Rosalind Advisors Inc. increased its position in Trevi Therapeutics by 41.7% during the fourth quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company's stock worth $4,378,000 after purchasing an additional 312,500 shares during the last quarter. Finally, American Century Companies Inc. increased its position in Trevi Therapeutics by 44.7% during the fourth quarter. American Century Companies Inc. now owns 78,143 shares of the company's stock worth $322,000 after purchasing an additional 24,153 shares during the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.